Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
Globe Newswire•07/10/2026•07:32 ET
8
Key Highlights
- ➤MitoCareX deploys computational drug discovery infrastructure on Google Cloud Platform
- ➤GCP deployment is designed to align computing capacity with evolving research needs
- ➤Environment centralizes scientific data and standardizes user-permission management
- ➤Nexentis (NXTS) owns 100% of MitoCareX Bio Ltd.
Expert Statements
David Palach, Chief Executive Officer of Nexentis Technologies Inc.
“Transitioning MitoCareX’s computational platform to a GCP-based environment represents an important step in strengthening the operating foundation for the next phase of MitoCareX’s development.”
David Palach, Chief Executive Officer of Nexentis Technologies Inc.
“This deployment is intended to provide MitoCareX’s scientific teams with an adaptable environment aligned with the changing needs of our discovery programs.”
David Palach, Chief Executive Officer of Nexentis Technologies Inc.
“We believe that combining operational flexibility with rigorous oversight of scientific data will support disciplined execution of our research strategy as these programs progress.”
Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs
Ness Ziona, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that MitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, now deploys its Computational Drug Discovery Infrastructure on Google Cloud Platform (“GCP”).
Get started
Create a free account to read the full story.